Biomx Inc (PHGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomx Inc (PHGE) has a cash flow conversion efficiency ratio of -0.685x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.18 Million) by net assets ($10.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biomx Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Biomx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PHGE total debt and obligations for a breakdown of total debt and financial obligations.
Biomx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ireka Corporation Bhd
KLSE:8834
|
0.003x |
|
Steppe Cement
LSE:STCM
|
0.038x |
|
MEDICOX Co. Ltd
KQ:054180
|
-0.040x |
|
Dixie Gold Inc
V:DG
|
-0.501x |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
-0.009x |
|
Chariot Oil & Gas Limited
LSE:CHAR
|
-0.127x |
|
Bango plc
LSE:BGO
|
0.097x |
|
BRAXIA SCIENTIFIC CORP.
F:4960
|
N/A |
Annual Cash Flow Conversion Efficiency for Biomx Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Biomx Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Biomx Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $24.15 Million | $-36.98 Million | -1.531x | +77.83% |
| 2023-12-31 | $3.08 Million | $-21.29 Million | -6.909x | -399.64% |
| 2022-12-31 | $21.04 Million | $-29.09 Million | -1.383x | -138.38% |
| 2021-12-31 | $47.53 Million | $-27.57 Million | -0.580x | -36.36% |
| 2020-12-31 | $57.47 Million | $-24.45 Million | -0.425x | -104.40% |
| 2019-12-31 | $84.46 Million | $-17.58 Million | -0.208x | +21.19% |
| 2018-12-31 | $42.80 Million | $-11.30 Million | -0.264x | +25.73% |
| 2017-12-31 | $11.53 Million | $-4.10 Million | -0.356x | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more